[1]
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195(5): 557-82.
[2]
Hurts JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
[3]
Müllerová H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: A retrospective observational cohort study. BMJ Open 2014; 4 e006171
[4]
Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013; 8: 641-52.
[5]
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
[6]
Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 653-61.
[7]
Soler-Cataluna JJ, Martìnez-Garcia MA, Sànchez PR, et al. Severe acute exacerbation and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-31.
[8]
Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism of COPD among adult aged > 18 years in the United States for 2010 and projections through 2020. Chest 2015; 147(1): 31-45.
[9]
Mannino DM, Higuchi K. YU T-C, et al Economic burden of COPD in the presence of comorbodities. Chest 2015; 148(1): 138-50.
[10]
Vestbo J, Vogelmeier C, Small M, Higgins V. Undertanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med 2014; 108: 729-36.
[11]
Brusselle G, Prince D. Gruffydd-Jones, et al The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulm Dis 2015; 10: 2207-17.
[12]
Hahn B, Hull M, Blauer-Peterson C, et al. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respir Med 2018; 139: 65-71.
[13]
James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management and outcomes of COPD patients in primary care, 2000-2009: A retrospective cohort study. NPJ Prim Care Respir Med 2014; 24: 14015.
[14]
Calverley P, Vlies B. A rationalapproach to single, dual and triple therapy in COPD. Respirology 2016; 21: 581-9.
[15]
Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52: 521-7.
[16]
Barnes PJ. Bronchodilators: basic pharmacology. In: Carveley PMA, Pride NB, Eds. Chronic Obstructive Pulmonary Disease. London: Chapman and Hall 1995; pp. 391-418.
[17]
Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy. Eur J Pharmacol 2015; 761: 168-73.
[18]
Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-72.
[19]
Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoid increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 12: L41-6.
[20]
Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilatation with QVA 149 versus single bronchodilator therapy: the SHINE study. Eur Resp J 2013; 42(6): 1484-94.
[21]
Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 in COPD. Resp Med 2013; 107: 1538-46.
[22]
D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: The 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014; 15: 123-41.
[23]
Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD. Eur Resp J 2015; 45: 869-71.
[24]
Martinez F, Rabe KF, Fergusson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest 2017; 151(2): 340-57.
[25]
Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel group, randomized controlled trial. Lancet Resp Med 2013; 1(3): 210-23.
[26]
Singh D, Corradi M, Spinola M, et al. Extrafine beclomethasone dipropionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med 2016; 26: 16030.
[27]
Keating GM, McCormack PL. Salmeterol/fluticasone propionate: A review of its use in the treatment of chronic obstructive pulmonary disease. Drugs 2007; 67(16): 2383-405.
[28]
Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8): 545-55.
[29]
Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63(7): 592-8.
[30]
Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(8): 741-50.
[31]
Jung KS, Park HY, Park SY, et al. Korea Chronic Obstructive Pulmonary disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study. Respir med 2012; 106(3): 382-9.
[32]
Manoharan A, Short PM, Andersn WJ, Lipworth BJ. Impact of long acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: A real-life retrospective cohort study. Lung 2014; 192(5): 649-52.
[33]
Frith PA, Thompson PJ, Ratnavadivel R, et al. Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 2015; 70(6): 519-27.
[34]
Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir Med 2015; 109(9): 1155-63.
[35]
Lee SD, Xie CM, Yunus F, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patiets with severe or very severe COPD: A randomized, multicenter study in East Asia. Respirology 2016; 21(1): 119-27.
[36]
Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA. The effect of umeclidinium added to inhaled corticosteroid/long- acting β2-agonist in patients with symptomatic COPD: A randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med 2016; 26: 16031.
[37]
Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Chirch A. Efficacy and safety of umeclidinum added to fluticasone furoate/vilanterol in chronic obstructive disease: Results of two randoized studies. Respir Med 2015; 109(9): 1155-63.
[38]
Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106(1): 91-101.
[39]
Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A. Extrafine
beclomethasone diproprionate/formterol fumarate: a review of its
effects in chronic obstructive pulmonary disease. NPJ Pim care
Med 2016; 26: 16030.
[40]
Singh D, Piccinno A, Borril Z, et al. Tolerability and high dose of the HFA modulate beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. Pulm Pharmacol Ther 2008; 21(3): 551-7.
[41]
Singh D, Papi A, Corradi M, et al. Single inhaler therapy versus inhaled corticosteroid plus long-acting b2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomized controlled trial. Lancet 2016; 388: 963-73.
[42]
Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double blind, parallel group, randomised controlled trial. Lancet 2017; 389(10082): 1919-29.
[43]
Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial. Lancet 2018; 391(10125): 1076-84.
[44]
Singh D, Roche N, Halpin D, Agusti A, Wedziche JA, Martinez FJ. Current controversies in the pharmacological treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2016; 194(5): 541-9.
[45]
Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; 293(3): L660-7.
[46]
Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): A novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013; 345(2): 260-70.
[47]
Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting b2 agonist vilanterol in patients with COPD: Arandomized, placebo-controlled trial. Chest 2012; 142: 119-27.
[48]
Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013; 344(1): 218-30.
[49]
Brealey N, Gupta A, Renaux J, et al. Pharmacokinetics of fluticasone furoate, umeclidinum and vilanterol as a triple therapy in healty volunteers. Int J Clin Pharcacol Ther 2015; 53(9): 753-64.
[50]
Molino A, Calabrese G, Maniscalco M. Patient considerations in the treatment of COPD: Focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. Patient Prefer Adherence 2018; 12: 993-1001.
[51]
Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Care Med 2017; 196(4): 438-46.
[52]
Halpin DMG, Birk R, Brealey N, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgropups analyses. EUR Open Res 2018; 4: 00119-2017.
[53]
Lipson DA, Barnahart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378(18): 1671-80.
[54]
Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial. Respir Med 2013; 107: 550-9.
[55]
Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013; 107: 560-9.
33
6
1
1